Mixed messages for ASX lithium stocks in 2023

Marc Kennis Marc Kennis, September 29, 2023

ASX lithium stocks … there may be further downside!

 

Our own Stuart Roberts explains the changing dynamics of the lithium market on Ausbiz!

Stuart hints towards potential waning interest in lithium, and ASX lithium stocks, attributing the cause to impenetrable market trends and a diminishing value. Recommending caution, he explains how the market value has primarily shown bearish instincts throughout 2023, barring a brief respite from April to June.

 

Don’t miss out on important news about ASX-listed stocks!

SIGN UP FOR THE STOCKS DOWN UNDER NEWSLETTER!

 

Turning attention towards particular ASX lithium stocks, Stuart says Core Lithium‘s (ASX:CXO) is the fourth most targeted stock for shorting on ASX. He also underscores the severe compression of Latin Resources’ (ASX:LRS) stock value, decreasing by half since July – an ominous indication for the lithium market.

Stuart also airs concern over the potential risks in these fluctuating markets. He comments on the transforming environmental obligations of governments globally. Wrapping up his analysis, Stuart alludes to a potential pivot back to conventional energy stocks, such as oil, gas, uranium and even coal. He accentuates Australia’s abundant resource reserves and the perpetual demand for these commodities.

 

Watch the entire interview here!

 

Blog Categories

Get the Latest Insider Trades on ASX!

Recent Posts

These 2 ASX Healthcare Stocks Are Quietly Cashing In on the AI Revolution

ASX Healthcare Stocks Benefiting From AI Artificial intelligence is reshaping healthcare faster than most investors realise. Hospital imaging systems, pathology…

Which ASX Uranium Stocks Benefit Most From the Iran War and the Hormuz Oil Crisis?

ASX Uranium Stocks to Watch This Week Brent crude is sitting just above US$111 a barrel as of this morning,…

Telix pharmaceuticals (ASX: TLX) A$230m Quarter Puts Guidance Back In Play

Is Telix in Turnaround Mode or Dead-Cat Bounce? The question investors are now asking about Telix pharmaceuticals is whether the…